Poziotinib, a tyrosine kinase inhibitor targeting EGFR/HER2 exon 20 insertion mutation, was found to have an ORR of 27% in HER2 exon 20 mutant NSCLC, gaining fast track designation by FDA (91, 92). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.